Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ifosfamide + gemcitabine
- Development stage
- Unknown
- Lead developer
- NuGen Medical Devices
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of ifosfamide (an alkylating agent) and gemcitabine (a nucleoside analog). This combination works through complementary mechanisms to inhibit DNA synthesis and cell division, showing synergistic effects against cancer cells. It is primarily used as salvage therapy in patients with relapsed or refractory malignancies.
- Other names
- Gemcitabine and IfosfamideGemcitabine plus Ifosfamide
02
Targets
RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on ifosfamide + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ifosfamide + gemcitabine.